A significant new treatment for advanced squamous cell carcinoma involves immunotherapy, specifically a class of drugs known as PD-1 inhibitors. These innovative therapies empower the body's own immune system to target and fight cancer cells more effectively.
Understanding Immunotherapy for Squamous Cell Carcinoma
Immunotherapy represents a major advance in cancer treatment, shifting the focus from directly attacking cancer cells with chemotherapy or radiation to enhancing the body's natural defenses. For squamous cell carcinoma, this approach primarily uses drugs that modulate immune checkpoints.How PD-1 Inhibitors Work
PD-1 inhibitors are a type of immunotherapy that targets the PD-1 (Programmed Death-1) protein. This protein is found on immune cells called **T cells** and typically acts as an "off switch" to prevent the immune system from attacking healthy cells. However, cancer cells can sometimes exploit this pathway to evade detection and destruction by the immune system.By blocking PD-1, these drugs essentially remove the "brake" on the T cells, allowing them to recognize and launch a stronger attack against cancer cells. This boosts the immune response, helping the body to fight off the cancer more effectively.
Key PD-1 Inhibitor Drugs
Two notable PD-1 inhibitor drugs used in the treatment of advanced squamous cell carcinoma include:- Cemiplimab (Libtayo)
- Pembrolizumab (Keytruda)
These medications are specifically designed to improve the immune system's ability to identify and eliminate malignant cells, offering a new avenue for patients with this type of skin cancer.
| Drug Name | Brand Name | Mechanism of Action | Primary Use |
|---|---|---|---|
| Cemiplimab | Libtayo | Blocks the PD-1 protein to activate T-cell response | Advanced squamous cell carcinoma |
| Pembrolizumab | Keytruda | Blocks the PD-1 protein to activate T-cell response | Various cancers, including advanced squamous cell carcinoma |
For more detailed information on treatments for squamous cell carcinoma and other skin cancers, you can consult reputable sources such as the American Cancer Society.
